CN115876990B - 鉴别诊断慢性血栓栓塞性肺动脉高压和肺栓塞的标志物及其应用 - Google Patents
鉴别诊断慢性血栓栓塞性肺动脉高压和肺栓塞的标志物及其应用 Download PDFInfo
- Publication number
- CN115876990B CN115876990B CN202310215534.5A CN202310215534A CN115876990B CN 115876990 B CN115876990 B CN 115876990B CN 202310215534 A CN202310215534 A CN 202310215534A CN 115876990 B CN115876990 B CN 115876990B
- Authority
- CN
- China
- Prior art keywords
- chronic thromboembolic
- sugar chain
- marker
- pulmonary embolism
- pulmonary hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000010378 Pulmonary Embolism Diseases 0.000 title claims abstract description 65
- 208000002815 pulmonary hypertension Diseases 0.000 title claims abstract description 63
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 title claims abstract description 62
- 238000003748 differential diagnosis Methods 0.000 title claims abstract description 31
- 239000003550 marker Substances 0.000 title claims abstract description 30
- 238000001514 detection method Methods 0.000 claims abstract description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 18
- 238000003759 clinical diagnosis Methods 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 19
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 14
- 230000001684 chronic effect Effects 0.000 description 14
- 230000009424 thromboembolic effect Effects 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 238000004949 mass spectrometry Methods 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 7
- 238000001212 derivatisation Methods 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 238000001819 mass spectrum Methods 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000009450 sialylation Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 5
- 230000033581 fucosylation Effects 0.000 description 5
- 229930182830 galactose Natural products 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 4
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000007477 logistic regression Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 3
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000002500 ions Chemical group 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036252 glycation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000083547 Columella Species 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100059509 Mus musculus Ccs gene Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004693 coupled cluster singles and doubles theory Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 238000012615 high-resolution technique Methods 0.000 description 1
- 238000006698 hydrazinolysis reaction Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000006699 reductive acetylation reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310215534.5A CN115876990B (zh) | 2023-03-08 | 2023-03-08 | 鉴别诊断慢性血栓栓塞性肺动脉高压和肺栓塞的标志物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310215534.5A CN115876990B (zh) | 2023-03-08 | 2023-03-08 | 鉴别诊断慢性血栓栓塞性肺动脉高压和肺栓塞的标志物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115876990A CN115876990A (zh) | 2023-03-31 |
CN115876990B true CN115876990B (zh) | 2023-07-04 |
Family
ID=85762026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310215534.5A Active CN115876990B (zh) | 2023-03-08 | 2023-03-08 | 鉴别诊断慢性血栓栓塞性肺动脉高压和肺栓塞的标志物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115876990B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118259010B (zh) * | 2024-04-07 | 2024-08-27 | 广东省人民医院 | 大动脉炎相关肺高压的预后标志物及其相关产品和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109975553A (zh) * | 2017-12-28 | 2019-07-05 | 北京师范大学 | 慢性阻塞性肺病的尿液蛋白标志物及其在早期诊断中的用途 |
CN113311056A (zh) * | 2021-05-10 | 2021-08-27 | 中国医学科学院北京协和医院 | 用于遗传性血管水肿的标志物及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113702482B (zh) * | 2021-08-30 | 2022-08-23 | 中国医学科学院北京协和医院 | 一种IgG N-糖链特征组合及其应用 |
CN113528653B (zh) * | 2021-09-09 | 2021-12-07 | 中日友好医院(中日友好临床医学研究所) | 与慢性血栓栓塞性肺动脉高压相关的生物标志物及其应用 |
CN115184619B (zh) * | 2022-08-01 | 2023-02-03 | 中国医学科学院北京协和医院 | 子宫内膜癌术前筛查及诊断的标志物及其应用 |
-
2023
- 2023-03-08 CN CN202310215534.5A patent/CN115876990B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109975553A (zh) * | 2017-12-28 | 2019-07-05 | 北京师范大学 | 慢性阻塞性肺病的尿液蛋白标志物及其在早期诊断中的用途 |
CN113311056A (zh) * | 2021-05-10 | 2021-08-27 | 中国医学科学院北京协和医院 | 用于遗传性血管水肿的标志物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN115876990A (zh) | 2023-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113311056B (zh) | 用于遗传性血管水肿的标志物及其应用 | |
An et al. | Glycomics and disease markers | |
JP5116837B2 (ja) | グリカンを評価するためのms法 | |
Goetz et al. | Glycomic profiling of invasive and non-invasive breast cancer cells | |
US20120107858A1 (en) | Cancer diagnosis method using the glycosylation of a glycoprotein | |
US20050272095A1 (en) | Methods of identifying biomarkers | |
Sturiale et al. | The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation | |
JP2009528544A (ja) | 質量分析法を用いて異性体を識別するための方法 | |
CN110028539B (zh) | 同位素标记仿生糖或糖组、其制备方法及应用 | |
CN114487417A (zh) | 用于甲状腺癌诊断、分层及预后的标志物及其应用 | |
JP2014066704A (ja) | 糖鎖構造の解析方法 | |
CN115876990B (zh) | 鉴别诊断慢性血栓栓塞性肺动脉高压和肺栓塞的标志物及其应用 | |
CN115876991B (zh) | 用于肺栓塞诊断的糖链标志物及其应用 | |
CN115184619B (zh) | 子宫内膜癌术前筛查及诊断的标志物及其应用 | |
KR101456096B1 (ko) | 인간 혈청 당쇄 지도 및 이를 이용하여 혈청 시료를 검증하는 방법 | |
EP3889614A1 (en) | Methods and systems for measuring serotonin in a sample | |
JP2009145169A (ja) | 糖類及び糖鎖のフェニルヒドラゾン化方法、該方法によりフェニルヒドラゾン化した糖類及び糖鎖の分析方法、並びに、前記方法を利用した糖類及び糖鎖の比較定量方法 | |
CN114660290B (zh) | 预测甲状腺癌术后复发的糖链标志物及其应用 | |
KR102100158B1 (ko) | N-당사슬 크로마토그램 피크의 상대정량에 의한 질병 스크리닝 방법 | |
KR101712368B1 (ko) | 당단백질의 전분자량 측정을 통한 당사슬 모니터링에 의한 고민감도 암 진단마커 분석방법 | |
CN115184611B (zh) | 子宫内膜癌分层相关的标志物及其应用 | |
EP3819639B1 (en) | Sugar chain specific to prostate cancer, and test method using same | |
KR101544591B1 (ko) | 질량분석기 및 크로마토그래피 시스템을 이용한 초고속 당 정성 및 정량 분석 방법 | |
CN118259010B (zh) | 大动脉炎相关肺高压的预后标志物及其相关产品和应用 | |
KR102091636B1 (ko) | N-당사슬 이성질체의 상대정량을 이용한 질병 스크리닝 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Jing Zhicheng Inventor after: Zhang Zejian Inventor after: Liu Chao Inventor after: Lian Tianyu Inventor after: Sun Kai Inventor after: Xu Xiqi Inventor after: Ding Dong Inventor before: Jing Zhicheng Inventor before: Zhang Zejian Inventor before: Liu Chao Inventor before: Lian Tianzi Inventor before: Sun Kai Inventor before: Xu Xiqi Inventor before: Ding Dong |
|
GR01 | Patent grant | ||
GR01 | Patent grant |